about
Enhanced granulysin mRNA expression in urinary sediment in early and delayed acute renal allograft rejectionTIRC7 is induced in rejected human kidneys and anti-TIRC7 mAb with FK506 prolongs survival of kidney allografts in ratsDifferential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients.Predicting the outcome of renal transplantationHLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.The influence of recovery and training phases on body composition, peripheral vascular function and immune system of professional soccer playersIdentification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank.BCR-ABL positive cells and chronic myeloid leukemia in immune suppressed organ transplant recipients.Molecular phenotypes of acute rejection predict kidney graft prognosis.High-mobility group box-1 protein serum levels do not reflect monocytic function in patients with sepsis-induced immunosuppression.Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms.Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8Vitamin A metabolism is changed in donors after living-kidney transplantation: an observational study.Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct mannersProtection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cellsComparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients.Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipientsRisk stratification for renal transplantation after cardiac or lung transplantation: single-center experience and review of the literature.Clonotype analysis of cytomegalovirus-specific cytotoxic T lymphocytes.Diagnostic value of T-cell monitoring assays in kidney transplantation.State of the art on the research for biomarkers allowing individual, tailor-made minimization of immunosuppression.Virus-specific T-cell therapy in solid organ transplantation.CMV-specific T Cell Monitoring Offers Superior Risk Stratification of CMV-seronegative Kidney Transplant Recipients of a CMV-seropositive Donor.Vasodilation and Exercise Capacity in Patients with End-Stage Renal Disease: A Prospective Proof-of-Concept Study.Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.Generation of HCMV-specific T-cell lines from seropositive solid-organ-transplant recipients for adoptive T-cell therapy.Estimated nephron number of the remaining donor kidney: impact on living kidney donor outcomes.Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.Sepsis: time has come to focus on the later stages.Kidney transplant recipients after nonrenal solid organ transplantation show low alloreactivity but an increased risk of infection.Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection.Simultaneous pancreas/kidney transplant recipients present with late-onset BK polyomavirus-associated nephropathy.IL-15 dependent induction of IL-18 secretion as a feedback mechanism controlling human MAIT-cell effector functions.ABO desensitization affects cellular immunity and infection control after renal transplantation.Different risk factor profiles distinguish early-onset from late-onset BKV-replication.Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome.Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
P50
Q28269113-E7499786-3B6E-4065-9E8B-3432B7169C62Q28276576-2A2B160A-516A-4D45-BB8E-E9588F5ECE29Q30353821-9487F1D9-C694-4838-9206-1D86A21F4BD0Q30505231-477BF384-5400-4CD8-A639-E0FA6BC0BAA9Q33215800-F9FDEF30-0D7E-48F5-832B-993F5FFEA347Q33394235-0ACE6AED-75A0-4E46-8B2B-FCD4CFB67598Q33419092-A9F2BDCA-B4C0-47BA-9758-5B32A24F4C42Q33449291-2C1F8B3D-0C20-4B13-BFF3-3C76614339CFQ33508296-9A3E2538-89F5-4159-847D-511F593A55A5Q33562254-03ABBF4B-6608-418A-AA00-E0DCD2AA204BQ34003036-7FB28AB1-9774-4379-BCBD-EAB716223953Q34603340-E8351BA5-0971-4268-A32B-9739BF675918Q35082545-A1E306D9-6999-4CC2-9C5A-FB90533AD7EBQ35650488-1789C634-D3BC-4318-AEB8-F6387C563465Q35849039-25297D84-F76E-4A6A-8CCB-9567A9B12E01Q36018275-B752E92D-06D8-45D3-ADF8-6398D5DAD57CQ36403419-F6741D4B-6A3C-4A2D-B09B-B580CFC5C533Q36482172-C0771B2F-7A60-499E-85B1-BAA0DC561038Q36736743-0CC7A362-675A-48E5-8C99-BF08C89D42ECQ36876109-6BC8E9DF-3191-48FE-9D1A-13D6F9C7AC64Q37086635-DBE646F6-75C4-4C9E-870C-2BBB0F0D43FFQ37471338-7BF33F4A-FCA7-44ED-AB1F-24223A0E572DQ37798698-687A3AA6-F00C-4C0A-B446-FD50A428DCA0Q38568902-D4A4A72A-E232-4328-AC83-51862BE784FDQ38736397-AE025C37-EDF0-4B9A-BFD2-9983D7556627Q39085572-94B5D5E7-C6A3-4176-834A-33A925A7EC23Q39386528-474AA9E7-7149-4720-A008-68D85B21BDB2Q39789612-8B40CAFD-29C3-4AAC-BD55-B502122BC652Q39974003-D8A9B67C-ADF8-4047-94E0-EE009953ACBDQ40042339-F85FF76D-DB25-40A3-B41F-78664935965BQ40096916-CA3485C4-4E68-47B3-A8E1-A4ED8DF5A0D6Q40537303-A2D6175B-59B5-4AB5-8C1E-FB7CFA993673Q40572376-A01249D6-9098-4752-9255-F648B0DC8A6FQ40835812-05E44285-5EB3-473A-81E2-8B040FFC95A7Q40866100-5DE2848C-0BF3-4FCB-A482-9E41C3F45714Q40879749-D60F68C7-D3E1-4CA1-A8DA-3CE76D8C5F04Q40955618-BAC876AB-44AB-45AA-843D-1B79C3694ED5Q40985364-794C1826-7439-4DD5-B640-66AF3F5F426EQ41604155-11710807-C57F-4350-8AD8-772DCF81B9F4Q42171624-4574D1CE-2D60-41F0-8D5B-85C785E88DDA
P50
description
immunologist
@en
name
Petra Reinke
@ast
Petra Reinke
@en
Petra Reinke
@es
Petra Reinke
@nl
type
label
Petra Reinke
@ast
Petra Reinke
@en
Petra Reinke
@es
Petra Reinke
@nl
prefLabel
Petra Reinke
@ast
Petra Reinke
@en
Petra Reinke
@es
Petra Reinke
@nl